NEUROLOGY / BASIC RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Against the backdrop of accelerating population aging, the risk of neurodegenerative diseases (NDDs) has risen significantly. While brain structure plays a critical role in NDDs, the interplay between them remains unclear. This study employed Mendelian randomization (MR) to investigate potential causal relationships between brain structure, region-specific gene expression, and four NDDs – Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) – providing new directions and genetically informed hypotheses for disease research.

Material and methods:
MR analyses were conducted using inverse-variance weighted (IVW), MR-Egger, weighted median, weighted mode, and Wald ratio methods. Summary-data-based MR (SMR) was applied to identify brain genes influencing NDDs. We calculated F-statistics, 95% confidence intervals (CIs), odds ratios, and p-values. Sensitivity analyses included the heterogeneity I² statistic, Cochran’s Q test, Egger intercept test, MR-PRESSO, and leave-one-out validation.

Results:
Data from 512 unsupervised deep-learning imaging phenotypes (UDIPs) were analyzed. Thirty-four UDIPs showed associations consistent with a potential causal role in AD, 56 in PD, 22 in ALS, and 92 in MS. After false discovery rate (FDR) correction, 4 remained significant for AD and PD, 3 for ALS, and 28 for MS (p < 0.05). Brain regions (excluding the cervical spinal cord C-1) exhibited shared causal genetic features across all four NDDs, primarily involving HLA-class genes.

Conclusions:
This study provides genetic evidence suggestive of potential causal associations between UDIPs, brain gene expression, and NDDs. These findings offer genetically predicted evidence that may generate hypotheses and inform future mechanistic research into NDD pathogenesis.
REFERENCES (53)
1.
Heemels MT. Neurodegenerative diseases. Nature 2016; 539: 179.
 
2.
Garton T, Gadani SP, Gill AJ, et al. Neurodegeneration and demyelination in multiple sclerosis. Neuron 2024; 112: 3231-51.
 
3.
Rodriguez Murua S, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu Rev Pathol 2022; 17: 121-39.
 
4.
Sarasso E, Filippi M, Agosta F. Clinical and MRI features of gait and balance disorders in neurodegenerative diseases. J Neurol 2023; 270: 1798-807.
 
5.
Trojsi F, Christidi F, Migliaccio R, et al. Behavioural and cognitive changes in neurodegenerative diseases and brain injury. Behav Neurol 2018; 2018: 4935915.
 
6.
Kang S, Eum S, Chang Y, et al. Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the Global Burden of Disease Study data. BMJ Open 2022; 12: e059548.
 
7.
Gonzales MM, Garbarino VR, Pollet E, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest 2022; 132: e158453.
 
8.
Wang S, Jiang Y, Yang A, et al. The expanding burden of neurodegenerative diseases: an unmet medical and social need. Aging Dis 2024; 16: 2937-52.
 
9.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9.
 
10.
Vitali P, Pan MI, Palesi F, et al. Substantia nigra volumetry with 3-T MRI in de novo and advanced Parkinson disease. Radiology 2020; 296: 401-10.
 
11.
Roosendaal SD, Geurts JJ, Vrenken H, et al. Regional DTI differences in multiple sclerosis patients. Neuroimage 2009; 44: 1397-403.
 
12.
Yang G, Xie W, Li B, et al. Casual associations between brain structure and sarcopenia: a large-scale genetic correlation and mendelian randomization study. Aging Cell 2024; 23: e14252.
 
13.
Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. Nat Rev Methods Primers 2022; 2: 6.
 
14.
Zhang B, Zhang R, Ren H, et al. Mendelian randomization analysis of the causal relationship between trimethylamine N-oxide and its precursors and Parkinson’s disease. Arch Med Sci 2024; 20: 1985-92.
 
15.
Huang Z, He G, Sun S, et al. Causal associations of ambient particulate matter 10 and Alzheimer’s disease: result from a two-sample multivariable Mendelian randomization study. Arch Med Sci 2024; 20: 1604-18.
 
16.
Seyedsalehi A, Warrier V, Bethlehem RAI, et al. Educational attainment, structural brain reserve and Alzheimer’s disease: a Mendelian randomization analysis. Brain 2023; 146: 2059-74.
 
17.
Ji D, Chen WZ, Zhang L, et al. Gut microbiota, circulating cytokines and dementia: a Mendelian randomization study. J Neuroinflammation 2024; 21: 2.
 
18.
Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 2019; 51: 414-30.
 
19.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019; 18: 1091-102.
 
20.
van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016; 48: 1043-8.
 
21.
International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019; 365: eaav7188.
 
22.
Patel K, Xie Z, Yuan H, et al. Unsupervised deep representation learning enables phenotype discovery for genetic association studies of brain imaging. Commun Biol 2024; 7: 414.
 
23.
Olejnik P, Golenia A, Malyszko J. The potential role of microbiota in age-related cognitive decline: a narrative review of the underlying molecular mechanisms. Int J Mol Sci 2025; 26: 1590.
 
24.
Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014; 159: 709-13.
 
25.
Peters R. Ageing and the brain. Postgrad Med J 2006; 82: 84-8.
 
26.
Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature 2016; 539: 180-6.
 
27.
Liu H, Hao Z, Qiu S, et al. Grey matter structural alterations in anxiety disorders: a voxel-based meta-analysis. Brain Imaging Behav 2024; 18: 456-74.
 
28.
Wei YC, Kung YC, Lin CP, et al. White matter alterations and their associations with biomarkers and behavior in subjective cognitive decline individuals: a fixel-based analysis. Behav Brain Funct 2024; 20: 12.
 
29.
Yue L, Pan Y, Li W, et al. Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage. J Prev Alzheimers Dis 2025; 12: 100079.
 
30.
Cao Q, Jiang K, Liu Y, et al. The comparison of the regional cerebral metabolism rate of glucose in Alzheimer’s disease with mild cognitive impairment. Zhonghua Yi Xue Za Zhi 2002; 82: 1613-6.
 
31.
Ju Z, Li Z, Lu J, et al. In vivo tau burden is associated with abnormal brain functional connectivity in alzheimer’s disease: a (18)F-Florzolotau Study. Brain Sci 2022; 12: 1355.
 
32.
Satizabal CL, Adams HHH, Hibar DP, et al. Genetic architecture of subcortical brain structures in 38,851 individuals. Nat Genet 2019; 51: 1624-36.
 
33.
Garcia-Marin LM, Campos AI, Diaz-Torres S, et al. Genomic analysis of intracranial and subcortical brain volumes yields polygenic scores accounting for variation across ancestries. Nat Genet 2024; 56: 2333-44.
 
34.
Krensky AM. The HLA system, antigen processing and presentation. Kidney Int Suppl 1997; 58: S2-7.
 
35.
Radwan J, Kohi C, Ejsmond M, et al. Integration of the immune memory into the pathogen-driven MHC polymorphism hypothesis. HLA 2023; 102: 653-9.
 
36.
Aliseychik MP, Andreeva TV, Rogaev EI. Immunogenetic factors of neurodegenerative diseases: the role of HLA class II. Biochemistry 2018; 83: 1104-16.
 
37.
Hopperton KE, Mohammad D, Trepanier MO, et al. Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. Mol Psychiatry 2018; 23: 177-98.
 
38.
Zota V, Nemirovsky A, Baron R, et al. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 2009; 183: 3522-30.
 
39.
Huang P, Yang YH, Chang YH, et al. Association of early-onset Alzheimer’s disease with germline-generated high affinity self-antigen load. Transl Psychiatry 2020; 10: 146.
 
40.
Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature 2017; 546: 656-61.
 
41.
Smith KJ, Pyrdol J, Gauthier L, et al. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998; 188: 1511-20.
 
42.
Wang P, Luo M, Zhou W, et al. Global characterization of peripheral B cells in Parkinson’s disease by single-cell RNA and BCR sequencing. Front Immunol 2022; 13: 814239.
 
43.
Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. The relation between alpha-synuclein and microglia in Parkinson’s disease: recent developments. Neuroscience 2015; 302: 47-58.
 
44.
Lu RC, Yang W, Tan L, et al. Association of HLA-DRB1 polymorphism with Alzheimer’s disease: a replication and meta-analysis. Oncotarget 2017; 8: 93219-26.
 
45.
Cardoso EM, Lourenco-Gomes V, Esgalhado AJ, et al. HLA-A23/HLA-A24 serotypes and dementia interaction in the elderly: association with increased soluble HLA class I molecules in plasma. HLA 2023; 102: 660-70.
 
46.
Minter MR, Zhang C, Leone V, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci Rep 2016; 6: 30028.
 
47.
Yang X, Zheng J, Tian S, et al. HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort. J Neurol Sci 2017; 373: 124-8.
 
48.
Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet 2017; 49: 1373-84.
 
49.
Guo F, Kang J, Xu J, et al. Genome-wide identification of m(6)A-associated single nucleotide polymorphisms in complex diseases of nervous system. Neurosci Lett 2023; 817: 137513.
 
50.
Wang B, Bai X, Yang Y, et al. Possible linking and treatment between Parkinson’s disease and inflammatory bowel disease: a study of Mendelian randomization based on gut-brain axis. J Transl Med 2025; 23: 45.
 
51.
Huang X, Chen PC, Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 2004; 62: 2198-202.
 
52.
Hossain N, Jeong Y. Protective genes against Alzheimer’s disease: case review and therapeutic implications. Dement Neurocogn Disord 2025; 24: 75-90.
 
53.
Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115: 1449-57.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top